

Gambro acquires clinic in New Jersey

Stockholm, Sweden, April 2, 2001 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that its wholly owned US subsidiary, Gambro Healthcare, Inc., has acquired, effective April 1, 2001, the assets of the dialysis center owned by Muhlenberg Regional Medical Center in the state of New Jersey. The dialysis center provides hemodialysis and peritoneal dialysis treatments to about 150 patients in the Plainfield, New Jersey area. Gambro Healthcare will also provide acute renal treatments to Muhlenberg Regional Medical Center and JFK Medical Center in the central New Jersey area pursuant to separate Acute Services Agreements for each location.

Muhlenberg Regional Medical Center is a university affiliated, teaching medical center that provides quality healthcare services in central New Jersey. The Medical Center employs more than 2,000 doctors, nurses, technologists and service personnel and receives the volunteer services of another thousand individuals. Muhlenberg Regional Medical Center is part of Solaris Health System, which was created in 1997 through the affiliation of Muhlenberg Regional Medical Center and JFK Medical Center. Solaris Health System includes acute care hospitals, dialysis centers, nursing and convalescent facilities and specialized treatment programs in the central New Jersey area.

“We are very excited to be adding the dialysis center into the Gambro Healthcare family. This acquisition further demonstrates Gambro Healthcare’s commitment to providing quality care for our patients and being among the world’s leaders in the industry,” stated Larry Buckelew, President and CEO of Gambro Healthcare US. “Focus for GHC US in the immediate future remains on internal processes and leverage on the new organizational and management structure in order to improve both care and business quality. During this phase there will be fewer acquisitions than were implemented previously, and investments in new business opportunities will be made on highly selective criteria.”

With this acquisition, Gambro Healthcare now provides hemodialysis treatments to over 1,200 patients in 13 outpatient facilities throughout the state of New Jersey. Gambro Healthcare now owns, operates, manages and/or provides consulting services to about 500 dialysis centers in the United States that serve a total of about 38,000 patients. There are patients under treatment in centers across 31 states and the District of Columbia.

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 22 billion (USD 2.4 billion), has approximately 18,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com

April 2, 2001

Gambro Healthcare is a leading provider of kidney dialysis services in the US. Gambro Healthcare is a fully integrated service provider of renal replacement therapy. Its activities include physician practice management, dialysis services and clinical laboratory services.

For further information please contact:

Bengt Mod  r, Investor Relations, tel. +46-8-613 65 00, +46-733-66 65 33

Karin Avasalu, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 99

Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 22 billion (USD 2.4 billion), has approximately 18,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com